Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001214659-25-015047
Filing Date
2025-10-17
Accepted
2025-10-17 14:01:00
Documents
1
Period of Report
2025-10-15

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT marketforms-71050.html 4  
1 PRIMARY DOCUMENT marketforms-71050.xml 4 3821
  Complete submission text file 0001214659-25-015047.txt   5332
Mailing Address 30 TECHNOLOGY DRIVE WARREN NJ 07059
Business Address 30 TECHNOLOGY DRIVE WARREN NJ 07059 908-941-1900
Aquestive Therapeutics, Inc. (Issuer) CIK: 0001398733 (see all company filings)

EIN.: 208623253 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O ACERAGEN, INC. 15 TW ALEXANDER DRIVE DURHAM NC 27709
Business Address
Kraus Carl N (Reporting) CIK: 0001946475 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38599 | Film No.: 251400047